NEW YORK, July 27, 2017 -- According to a new research report “Friedreich's Ataxia (FRDA) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Friedreich's ataxia currently exhibits a strong pipeline with 17 drug candidates.
Access Report Summary at: https://www.psmarketresearch.com/market-analysis/frda-therapeutics-pipeline-analysis
The study analyzed that the Friedreich's ataxia therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Friedreich’s ataxia is an autosomal recessive inherited genetic disorder that progressively damages the nervous system. Its initial symptoms include ataxia, impaired muscle coordination and impaired speech. This results in development of dysarthria, scoliosis, heart diseases and diabetes, but does not affect cognitive function.
According to the research findings, most of the drug candidates in Friedreich's ataxia therapeutics pipeline are being developed to be administered by oral route.
Catabasis Pharmaceuticals, Inc. received Kyle Bryant Translational Research award from the FARA for the evaluation of their drug candidate, which is being developed for the treatment of Friedreich’s ataxia.
The research also found that various companies are in the process of developing the drug candidates using natural sources for the treatment of Friedreich's ataxia therapeutics pipeline. Cardero Therapeutics, Inc. is in the process of developing a drug candidate as a sterol using natural source, for the treatment of Friedreich's ataxia.
Make Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=frda-therapeutics-pipeline-analysis
Some of the key players developing drugs for the treatment of Friedreich's ataxia include Cardero Therapeutics, Inc., Edison Pharmaceuticals, Inc., Retrotope, Inc. and others.
Browse Related Research
IgA Nephropathy Pipeline Analysis, 2017
IgA nephropathy does not have a specific treatment, since when the kidneys get damaged they cannot be repaired. So the only treatment available is to prevent or delay ESRD. The process of kidney damage can be slowed down by the use of fish oil supplements, immunosuppressive drugs, corticosteroids angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors.
https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
Sjögren’s Syndrome Therapeutics Pipeline Analysis, 2017
Primary Sjögren’s syndrome is the most common syndrome that varies within the same geographical area and has a strong female propensity. Studies show that the female to male ratio in primary Sjögren’s syndrome varies from as high as 20:1 to 9:1. Caucasian are more prone to the primary Sjögren’s syndrome with mean age of around 40 years. The annual incidence of primary Sjogren’s syndrome was 3.9 per 100,000 persons in year 2002 with higher prevalence in women as compared to men.
https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis
Alzheimer’s Disease Pipeline Analysis, 2017
Although significant progress has been witnessed in drug development for Alzheimer’s disease, studies are focused on various promising targets including amyloid beta protein, tau protein, beta secretase and 5-hydroxytryptamine 6 (5HT6) receptor with high potential, and reduced or no side effects. The cause for Alzheimer’s is still unknown, even after promising growth in the development of its pipeline. Also, specific targeted treatments are still not available in the market due to the unknown cause and inefficient diagnostic methods for early detection.
https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook


FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Italy Fines Apple €98.6 Million Over App Store Dominance
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 



